Literature DB >> 28500490

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.

Eva K Sage1, Thomas E Schmid1,2,3, Hans Geinitz4, Mathias Gehrmann1, Michael Sedelmayr1, Marciana N Duma1,2, Stephanie E Combs1,2,3, Gabriele Multhoff5,6,7.   

Abstract

BACKGROUND: Radiotherapy (RT) is an established treatment for patients with primary and recurrent prostate cancer. Herein, the effects of definitive and salvage RT on the composition of lymphocyte subpopulations were investigated in patients with prostate cancer to study potential immune effects. PATIENTS AND METHODS: A total of 33 prostate cancer patients were treated with definitive (n = 10) or salvage RT (n = 23) after biochemical relapse. The absolute number of lymphocytes and the distribution of lymphocyte subpopulations were analyzed by multiparameter flow cytometry before RT, at the end of RT, and in the follow-up period.
RESULTS: Absolute lymphocyte counts decreased significantly after RT in both patient groups and a significant drop was observed in the percentage of B cells directly after RT from 10.1 ± 1.3 to 6.0 ± 0.7% in patients with definitive RT and from 9.2 ± 0.8 to 5.8 ± 0.7% in patients with salvage RT. In contrast, the percentages of T and natural killer (NK) cells remained unaltered directly after RT in both patient groups. However, 1 year after RT, the percentage of CD3+ T cells was significantly lower in patients with definitive and salvage RT. The percentage of regulatory T cells was slightly upregulated in primary prostate cancer patients after definitive RT, but not after salvage RT.
CONCLUSION: Definitive and salvage RT exert similar effects on the composition of lymphocyte subpopulations in prostate cancer patients. Total lymphocyte counts are lower in both patient groups compared to healthy controls and further decreased after RT. B cells are more sensitive to definitive and salvage RT than T and NK cells.

Entities:  

Keywords:  Anti-tumor Immunity; B lymphocytes; Natural killer cells; Prostatectomy; T lymphocytes

Mesh:

Year:  2017        PMID: 28500490     DOI: 10.1007/s00066-017-1144-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  31 in total

Review 1.  Role of Local Radiation Therapy in Cancer Immunotherapy.

Authors:  Sandra Demaria; Encouse B Golden; Silvia C Formenti
Journal:  JAMA Oncol       Date:  2015-12       Impact factor: 31.777

2. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

3.  Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.

Authors:  Shawn Malone; Jennifer Croke; Nicolas Roustan-Delatour; Eric Belanger; Leonard Avruch; Colin Malone; Christopher Morash; Cathleen Kayser; Kathryn Underhill; Yan Li; Kyle Malone; Balazs Nyiri; Johanna Spaans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-22       Impact factor: 7.038

Review 4.  [The role of radiotherapy in the induction of antitumor immune responses].

Authors:  G Multhoff; U S Gaipl; G Niedermann
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

5.  Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients.

Authors:  Eva K Sage; Thomas E Schmid; Michael Sedelmayr; Mathias Gehrmann; Hans Geinitz; Marciana N Duma; Stephanie E Combs; Gabriele Multhoff
Journal:  Radiother Oncol       Date:  2015-12-09       Impact factor: 6.280

Review 6.  Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies.

Authors:  B Frey; Y Rubner; R Wunderlich; E-M Weiss; A G Pockley; R Fietkau; U S Gaipl
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.

Authors:  Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2011-07-25       Impact factor: 3.621

8.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

9.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

Review 10.  Systemic effects of local radiotherapy.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Lancet Oncol       Date:  2009-07       Impact factor: 41.316

View more
  13 in total

1.  Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Authors:  Franziska Eckert; Philipp Schaedle; Daniel Zips; Barbara Schmid-Horch; Hans-Georg Rammensee; Cihan Gani; Cécile Gouttefangeas
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 2.  Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies.

Authors:  Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl
Journal:  Strahlenther Onkol       Date:  2018-03-02       Impact factor: 3.621

Review 3.  NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

4.  Modulation of Peripheral Immune Cell Subpopulations After RapidArc/Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: Findings and Comparison With 3D Conformal/Conventional Fractionation Treatment.

Authors:  Fiorella D'Auria; Teodora Statuto; Luciana Rago; Antonietta Montagna; Giovanni Castaldo; Irene Schirò; Anna Zeccola; Teresa Virgilio; Gabriella Bianchino; Antonio Traficante; Alessandro Sgambato; Vincenzo Fusco; Luciana Valvano; Giovanni Calice
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

Review 5.  Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Authors:  Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

6.  The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer.

Authors:  Jialin Meng; Yi Liu; Shiyang Guan; Song Fan; Jun Zhou; Meng Zhang; Chaozhao Liang
Journal:  Cancer Med       Date:  2019-07-29       Impact factor: 4.452

7.  Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic Cancer.

Authors:  Sumei Zhang; Shufen Zhao; Xinzhen Fu
Journal:  Pak J Med Sci       Date:  2019 Sep-Oct       Impact factor: 1.088

8.  Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on Injury.

Authors:  Rachel A Schlaak; Anne Frei; Brian L Fish; Leanne Harmann; Tracy Gasperetti; Jamie L Pipke; Yunguang Sun; Hallgeir Rui; Michael J Flister; Benjamin N Gantner; Carmen Bergom
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

9.  Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis.

Authors:  Qin Wang; Shangbiao Li; Simiao Qiao; Zhihao Zheng; Xiaotong Duan; Xiaoxia Zhu
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

10.  Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study.

Authors:  Giuseppe Sanguineti; Diana Giannarelli; Maria Grazia Petrongari; Stefano Arcangeli; Angelo Sangiovanni; Biancamaria Saracino; Alessia Farneti; Adriana Faiella; Mario Conte; Giorgio Arcangeli
Journal:  Radiat Oncol       Date:  2019-01-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.